HC Deb 15 October 2002 vol 390 c803W
Mr. Drew

To ask the Secretary of State for Health what discussions he has had with(a) the Pituitary Foundation, (b) the Royal College of Physicians and (c) the Society for Endocrinology on the subject of growth hormone deficiency. [73352]

Jacqui Smith

My right hon. Friend the Secretary of State has had no discussions with the Pituitary Foundation, The Royal College of Physicians or the Society for Endocrinology on the subject of growth hormone deficiency.

In May the National Institute for Clinical Excellence (NICE) recommended to the National Health Service in England and Wales that human growth hormone (somatropin) is both a clinically and cost effective way to treat children with growth hormone (GH) deficiency. A decision on adult growth hormone deficiency is eexpected from NICE shortly.

Mr. Drew

To ask the Secretary of State for Health if he will make a statement on the average cost of treatment for individuals suffering from growth hormone deficiency in the last year for which figures are available. [73353]

Jacqui Smith

The cost of treatment depends on the dose, which is determined by the weight and size of the patient, as well as the individual growth hormone reserve. The average annual cost of growth hormone treatment, based on March 2002 figures, is around £3350 per patient.

Back to